Page last updated: 2024-11-04

propiomazine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Propiomazine is a phenothiazine derivative with antipsychotic, antiemetic, and sedative properties. It is a synthetic compound developed in the 1950s. Propiomazine is thought to act primarily as a dopamine antagonist, blocking dopamine receptors in the brain. This action contributes to its antipsychotic effects, particularly in managing schizophrenia and other psychotic disorders. Additionally, its antiemetic effects are attributed to its ability to suppress the vomiting reflex. Propiomazine is also known to possess anticholinergic properties, which may contribute to its sedative effects. While once widely used, its use has declined due to the availability of newer, more effective antipsychotic drugs with fewer side effects. Nonetheless, propiomazine continues to be studied for its potential therapeutic uses in specific contexts, such as its antiemetic properties in managing nausea and vomiting associated with chemotherapy.'

propiomazine: was heading 1966-94 (prov 1966-72); use PHENOTHIAZINES to search PROPIOMAZINE 1966-94; phenothiazine derivative used for sedation and as an antiemetic during labor [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

propiomazine : A member of the class of phenothiazines that is 10H-phenothiazine substituted by a 2-(dimethylamino)propyl group at nitrogen atom and a propanoyl group at position 2. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID4940
CHEMBL ID1201210
CHEBI ID8491
SCHEMBL ID93770
MeSH IDM0224690

Synonyms (78)

Synonym
BRD-A10471441-050-02-8
1-propanone, 1-[10-[2-(dimethylamino)propyl]-10h-phenothiazin-2-yl]-
DIVK1C_000296
KBIO1_000296
1-{10-[2-(dimethylamino)propyl]-10h-phenothiazin-2-yl}propan-1-one
SPECTRUM_000872
IDI1_000296
cb 1678
einecs 206-646-1
1-propanone, 1-(10-(2-(dimethylamino)propyl)phenothiazin-2-yl)-
propiomazinum [inn-latin]
1-(10-(2-(dimethylamino)propyl)phenothiazin-2-yl)-1-propanone
propionylpromethazine
wy-1359
propavan
10-dimethylaminoisopropyl-2-propionylphenothiazine
propiomazine [usan:inn:ban]
propiomazina [inn-spanish]
1-propanone, 1-(10-(2-(dimethylamino)propyl)-10h-phenothiazin-2-yl)-
phenoctyl
hsdb 3275
NCGC00178744-01
OPREA1_617420
BSPBIO_002237
SPECTRUM5_001104
CHEBI:8491 ,
propiomazina
propiomazinum
362-29-8
C07405
propiomazine
2-propionyl-10-(2-(dimethylamino)propyl)phenothiazine
3-propionyl-10-dimethylaminoisopropylphenothiazine
DB00777
10-(2-dimethylaminopropyl)-2-propionylphenothiazine
D02361
propiomazine (usan/inn)
KBIO2_001352
KBIO3_001737
KBIO2_006488
KBIOSS_001352
KBIO2_003920
KBIOGR_001001
SPECTRUM4_000491
SPECTRUM2_000930
SPECTRUM3_000559
NINDS_000296
SPBIO_000840
L000807
1-[10-[2-(dimethylamino)propyl]phenothiazin-2-yl]propan-1-one
dorevan
CHEMBL1201210
cb-1678 ,
242z0pm79y ,
unii-242z0pm79y
propiomazine [vandf]
(+/-)-propiomazine
propiomazine [hsdb]
propiomazine [mi]
propiomazine [usan]
propiomazine [mart.]
propiomazine [who-dd]
88245-06-1
1-[10-[2-(dimethylamino)propyl]phenothiazin-2-yl]-1-propanone
propiomazine [inn]
gtpl7284
SCHEMBL93770
UVOIBTBFPOZKGP-UHFFFAOYSA-N
1-[10-[2-(dimethylamino)propyl]-10h-phenothiazin-2-yl]-1-propanone
2-propionyl-10-[2-(dimethylamino)propyl]phenothiazine
1-propanone, 1-[10-[2-(dimethylamino)propyl]phenothiazin-2-yl]-
DTXSID1023520
1-{10-[2-(dimethylamino)propyl]-10h-phenothiazin-2-yl}-1-propanone
1-[10-[2-(dimethylamino)propyl]phenothiazin-2-yl-1-propanone
Q7250328
EN300-18559874
CS-0021941
HY-U00051

Research Excerpts

[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (6)

RoleDescription
phenothiazine antipsychotic drugnull
dopaminergic antagonistA drug that binds to but does not activate dopamine receptors, thereby blocking the actions of dopamine or exogenous agonists.
serotonergic antagonistDrugs that bind to but do not activate serotonin receptors, thereby blocking the actions of serotonin or serotonergic agonists.
muscarinic antagonistA drug that binds to but does not activate muscarinic cholinergic receptors, thereby blocking the actions of endogenous acetylcholine or exogenous agonists.
histamine antagonistHistamine antagonists are the drugs that bind to but do not activate histamine receptors, thereby blocking the actions of histamine or histamine agonists.
sedativeA central nervous system depressant used to induce drowsiness or sleep or to reduce psychological excitement or anxiety.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (3)

ClassDescription
phenothiazines
aromatic ketoneA ketone in which the carbonyl group is attached to an aromatic ring.
tertiary amino compoundA compound formally derived from ammonia by replacing three hydrogen atoms by organyl groups.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (1)

PathwayProteinsCompounds
Propiomazine H1-Antihistamine Action87

Bioassays (2)

Assay IDTitleYearJournalArticle
AID588220Literature-mined public compounds from Kruhlak et al phospholipidosis modelling dataset2008Toxicology mechanisms and methods, , Volume: 18, Issue:2-3
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (30)

TimeframeStudies, This Drug (%)All Drugs %
pre-199021 (70.00)18.7374
1990's3 (10.00)18.2507
2000's2 (6.67)29.6817
2010's3 (10.00)24.3611
2020's1 (3.33)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 41.79

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index41.79 (24.57)
Research Supply Index3.61 (2.92)
Research Growth Index4.81 (4.65)
Search Engine Demand Index59.29 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (41.79)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (2.86%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other34 (97.14%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]